Our Pipeline
Developing World Class Therapeutics
Harnessing and treating inflammatory and fibrotic diseases of today with a novel therapy of tomorrow.
Our Platform
Aqualung has developing and continues to develop novel immunotherapeutics designed to address serious unmet therapeutic needs across the globe. Our platform consists of a humanized monoclonal antibody (ALT-100 mAb), a novel nanocarrier (NTyP-100) and a fusion immunoglobulin protein (SELP-100)
